KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to $6.6 million.

  • Novavax's Depreciation & Amortization (CF) fell 48.15% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year decrease of 25.16%. This contributed to the annual value of $48.5 million for FY2024, which is 17.64% up from last year.
  • As of Q3 2025, Novavax's Depreciation & Amortization (CF) stood at $6.6 million, which was down 12.93% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Depreciation & Amortization (CF) registered a high of $12.7 million during Q3 2024, and its lowest value of $2.3 million during Q1 2021.
  • In the last 3 years, Novavax's Depreciation & Amortization (CF) had a median value of $10.8 million in 2023 and averaged $10.2 million.
  • In the last 5 years, Novavax's Depreciation & Amortization (CF) skyrocketed by 191.97% in 2022 and then crashed by 48.15% in 2025.
  • Over the past 5 years, Novavax's Depreciation & Amortization (CF) (Quarterly) stood at $3.7 million in 2021, then skyrocketed by 96.68% to $7.2 million in 2022, then spiked by 49.46% to $10.8 million in 2023, then rose by 15.96% to $12.5 million in 2024, then plummeted by 48.15% to $6.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $6.6 million for Q3 2025, versus $7.6 million for Q2 2025 and $8.3 million for Q1 2025.